Audentes Therapeutics Inc (NASDAQ:BOLD) has been given a $24.00 target price by Piper Jaffray Cos. in a research note issued to investors on Monday. The firm presently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price objective points to a potential upside of 30.86% from the company’s current price.

BOLD has been the subject of a number of other research reports. Wedbush reiterated an “outperform” rating and set a $20.00 price target on shares of Audentes Therapeutics in a research report on Thursday, September 1st. Cowen and Company assumed coverage on Audentes Therapeutics in a research report on Monday, August 15th. They set an “outperform” rating for the company.

Audentes Therapeutics (NASDAQ:BOLD) traded up 0.82% during mid-day trading on Monday, reaching $18.49. 19,271 shares of the company’s stock were exchanged. Audentes Therapeutics has a one year low of $13.06 and a one year high of $19.26. The stock’s market cap is $401.70 million. The stock has a 50-day moving average of $15.80 and a 200-day moving average of $15.45.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

In other news, major shareholder Versant Ventures Iv, Llc bought 35,000 shares of the company’s stock in a transaction that occurred on Monday, July 25th. The stock was bought at an average price of $15.00 per share, for a total transaction of $525,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider James E. Flynn bought 400,000 shares of the company’s stock in a transaction that occurred on Monday, July 25th. The stock was purchased at an average price of $15.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here.

About Audentes Therapeutics

Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

5 Day Chart for NASDAQ:BOLD

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with's FREE daily email newsletter.